Baxter International Inc (BAX)
NYSE:BAX
Want to see BAX full AI Analyst Report?
BAX Stock Chart & Stats
$18.71
$0.05(0.17%)
At close: 4:00 PM EST
$18.71
$0.05(0.17%)
Day’s Range― - ―
52-Week Range$15.73 - $32.04
Previous CloseN/A
Volume899.70K
Average Volume (3M)7.55M
Market Cap
$10.01B
Enterprise Value$17.37B
Total Cash (Recent Filing)$2.02B
Total Debt (Recent Filing)$9.69B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Jul 23, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)-2.10
Shares Outstanding516,469,000
10 Day Avg. Volume5,928,586
30 Day Avg. Volume7,551,870
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market Cap1.74
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit5.10
Enterprise Value/Ebitda23.35
Forecast
1Y Price Target
$20.86Price Target Upside11.48% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)1.92
Revenue Forecast (FY)$11.36B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueBaxter’s core revenue mix relies on consumables tied to dialysis, infusion systems and IV solutions, creating a durable, repeat-revenue stream. An installed base of devices drives ongoing pull-through for disposables, supporting predictable revenue and cash generation over multiple quarters.
Improving Free Cash FlowA sustained move to positive operating and free cash flow provides financial flexibility to fund operations, service debt and prioritize deleveraging. Strong FCF growth underpins durable capital allocation choices (debt paydown, targeted M&A, R&D) even while GAAP profitability recovers.
Product Launches & Operational ImprovementNew devices, AI integration and a company-wide continuous improvement program (GPS Kaizen events) boost long-term differentiation and manufacturing efficiency. Combined product innovation and throughput gains can expand the installed base and improve margins as fixes and scale persist.
Bears Say
Meaningful Leverage & Negative ROEMaterial leverage and negative returns on equity constrain strategic flexibility. With debt well above equity and continuing net losses, interest costs and covenant sensitivity can limit incremental investment, forcing prioritization of deleveraging over growth initiatives in coming quarters.
Margin Compression From Tariffs/costsSignificant margin deterioration driven by tariffs, higher manufacturing costs and absorption issues is a structural headwind. Unless fully mitigated by cost actions or pricing, these pressures can persist and materially dent operating leverage, slowing the pace of profitability recovery.
Novum LVP Field Actions & Return RiskA product hold and potential customer returns create structural uncertainty for a pump portfolio and its consumable pull-through. Beyond near-term revenue disruption, returns risk can erode installed base confidence, delay commercialization momentum and increase remediation costs over multiple quarters.
Baxter International News
BAX FAQ
What was Baxter International Inc’s price range in the past 12 months?
Baxter International Inc lowest stock price was $15.73 and its highest was $32.04 in the past 12 months.
What is Baxter International Inc’s market cap?
Baxter International Inc’s market cap is $10.01B.
When is Baxter International Inc’s upcoming earnings report date?
Baxter International Inc’s upcoming earnings report date is Jul 23, 2026 which is in 44 days.
How were Baxter International Inc’s earnings last quarter?
Baxter International Inc released its earnings results on Apr 30, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.311 by $0.059.
Is Baxter International Inc overvalued?
According to Wall Street analysts Baxter International Inc’s price is currently Undervalued.
Does Baxter International Inc pay dividends?
Baxter International Inc pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 2.75%. See more information on Baxter International Inc dividends here
What is Baxter International Inc’s EPS estimate?
Baxter International Inc’s EPS estimate is 0.37.
How many shares outstanding does Baxter International Inc have?
Baxter International Inc has 516,469,000 shares outstanding.
What happened to Baxter International Inc’s price movement after its last earnings report?
Baxter International Inc reported an EPS of $0.37 in its last earnings report, beating expectations of $0.311. Following the earnings report the stock price went up 4.02%.
Which hedge fund is a major shareholder of Baxter International Inc?
Currently, no hedge funds are holding shares in BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.86 (11.48% Upside)
$20.86 (11.48% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.16%
12-Months-Change
Fundamentals
Return on Equity
-16.43%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Company Description
Baxter International Inc
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.View all BAX earnings summariesBAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
BAX Stock 12 Month Forecast
Average Price Target
$20.86
▲(11.48% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
34.64% Mutual Funds
38.39% Other Institutional Investors
0.87% Public Companies and
Individual Investors